Antiretroviral therapy and pre-exposure prophylaxis: combined impact on HIV transmission and drug resistance in South Africa.

BACKGROUND The potential impact of antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) with overlapping and nonoverlapping antiretrovirals (ARVs) on human immunodeficiency virus (HIV) transmission and drug resistance is unknown. METHODS A detailed mathematical model was used to simulate the epidemiological impact of ART alone, PrEP alone, and combined ART + PrEP in South Africa. RESULTS ART alone initiated at a CD4 lymphocyte cell count <200 cells/µL (80% coverage and 96% effectiveness) prevents 20% of HIV infections over 10 years but increases drug resistance prevalence to 6.6%. PrEP alone (30% coverage and 75% effectiveness) also prevents 21% of infections but with lower resistance prevalence of 0.5%. The ratio of cumulative infections prevented to prevalent drug-resistant cases after 10 years is 7-fold higher for PrEP than for ART. Combined ART + PrEP with overlapping ARVs prevents 35% of infections but increases resistance prevalence to 8.2%, whereas ART + PrEP with nonoverlapping ARVs prevents slightly more infections (37%) and reduces resistance prevalence to 7.2%. CONCLUSIONS Combined ART + PrEP is likely to prevent more HIV infections than either strategy alone, but with higher prevalence of drug resistance. ART is predicted to contribute more to resistance than is PrEP. Optimizing both ART and PrEP effectiveness and delivery are the keys to preventing HIV transmission and drug resistance.

[1]  Michael Rayment,et al.  Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.

[2]  D. Katzenstein,et al.  Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa , 2010, AIDS (London).

[3]  F. Dabis,et al.  Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy , 2010, Sexually Transmitted Infections.

[4]  M. Egger,et al.  Outcomes of Antiretroviral Treatment Programs in Rural Southern Africa , 2012, Journal of acquired immune deficiency syndromes.

[5]  Simon Wain-Hobson.  Virus Dynamics: Mathematical Principles of Immunology and Virology , 2001, Nature Medicine.

[6]  T. F. Rinke de Wit,et al.  Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  O. Laeyendecker,et al.  Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.

[8]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[9]  B. Branson,et al.  Vital signs: HIV prevention through care and treatment--United States. , 2011, MMWR. Morbidity and mortality weekly report.

[10]  D. Pillay,et al.  The effect of transmitted HIV-1 drug resistance on pre-therapy viral load , 2010, AIDS.

[11]  Sabine Yerly,et al.  Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. , 2009, The Lancet. Infectious diseases.

[12]  F. Hecht,et al.  Differential persistence of transmitted HIV-1 drug resistance mutation classes. , 2011, Journal of Infectious Diseases.

[13]  J. Margolick,et al.  Human Immunodeficiency Virus Type 1 Population Genetics and Adaptation in Newly Infected Individuals , 2008, Journal of Virology.

[14]  John T Brooks,et al.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. , 2012, The New England journal of medicine.

[15]  James D. Campbell,et al.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.

[16]  P. Kaye.  Infectious diseases of humans: Dynamics and control , 1993 .

[17]  A. Wensing,et al.  Evolutionary pathways of transmitted drug-resistant HIV-1. , 2011, The Journal of antimicrobial chemotherapy.

[18]  S. Rosen,et al.  Retention in HIV Care between Testing and Treatment in Sub-Saharan Africa: A Systematic Review , 2011, PLoS medicine.

[19]  D. Pillay,et al.  Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis , 2012, The Lancet.

[20]  Eduard Hofer,et al.  Sensitivity analysis in the context of uncertainty analysis for computationally intensive models , 1999 .

[21]  Ian Sanne,et al.  The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa , 2010, AIDS.

[22]  Katrien Fransen,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[23]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[24]  S. Lawn,et al.  Changes in Programmatic Outcomes During 7 Years of Scale-up at a Community-Based Antiretroviral Treatment Service in South Africa , 2011, Journal of acquired immune deficiency syndromes.

[25]  M. Chopra,et al.  The failure of routine rapid HIV testing: a case study of improving low sensitivity in the field , 2010, BMC health services research.

[26]  B. Chi,et al.  Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in southern Africa , 2011, AIDS.

[27]  A. Wensing,et al.  Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. , 2010, The Lancet. Infectious diseases.

[28]  C. Deal,et al.  O11.1 Herpes Simplex Virus (HSV) Infection in the VOICE (MTN 003) Study: Pre-Exposure Prophylaxis (PrEP) For HIV with Daily Use of Oral Tenofovir, Oral Tenofovir-Emtricitabine, or Vaginal Tenofovir Gel , 2013, Sexually Transmitted Infections.

[29]  F. Wit,et al.  Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. , 2012, The Lancet. Infectious diseases.

[30]  T. Hallett,et al.  A Decline in New HIV Infections in South Africa: Estimating HIV Incidence from Three National HIV Surveys in 2002, 2005 and 2008 , 2010, PloS one.

[31]  J. Inciardi,et al.  Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. , 2007, Pain medicine.

[32]  Roy M. Anderson,et al.  Potential Impact of Antiretroviral Chemoprophylaxis on HIV-1 Transmission in Resource-Limited Settings , 2007, PloS one.

[33]  E Windisch,et al.  [South Africa]. , 1976, Osterreichische Krankenpflegezeitschrift.

[34]  S. Vermund,et al.  Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression , 2008, AIDS.

[35]  Kishor Mandaliya,et al.  HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. , 2011, The Lancet. Infectious diseases.

[36]  M. Wainberg,et al.  Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. , 2011, The Journal of antimicrobial chemotherapy.

[37]  R Hoh,et al.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.

[38]  Christopher Dye,et al.  Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model , 2009, The Lancet.

[39]  N. Parkin,et al.  The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy , 2009, AIDS.

[40]  M. Zwahlen,et al.  Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies , 2008, Sexually Transmitted Infections.

[41]  Organización Mundial de la Salud,et al.  Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report 2009 , 2009 .

[42]  Jacques Izopet,et al.  Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy , 2001, Journal of Virology.